Approved treatments
for hATTR-PN

Overview

There is no cure for hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN), but there are several approved disease-modifying therapies, which help slow disease progression and improve quality of life. All are classified as gene-silencing therapies, suppressing the production of the faulty transthyretin protein that drives the disease.

Amvuttra

Amvuttra (vutrisiran) is a treatment approved for adults with hATTR-PN that is given via an under-the-skin, or subcutaneous, injection, once every three months.

Learn more

Onpattro

Onpattro (patisiran) is an approved infusion therapy for adults with hATTR-PN. It is administered directly into the bloodstream once every three weeks.

Learn more

Wainua

Wainua (eplontersen) is a subcutaneous injectable treatment approved for adults with hATTR-PN. Sold as Wainzua in Europe, it can be self-administered by patients after appropriate training.

Learn more